Histone Modifications and Their Targeting in Lymphoid Malignancies.

Area of Science:

• Oncology
• Epigenetics
• Hematology

Background:

• Malignant transformation in lymphoid neoplasms involves somatic mutations affecting B-cell epigenetic machinery.
• Histone modification alterations drive disease-specific transcriptional programs in B-cell lymphomas.
• These changes impact cell cycle regulation, apoptosis, and DNA damage response, promoting immune evasion and lymphoma development.

Purpose of the Study:

• To review epigenetic alterations in B-cell non-Hodgkin lymphoma.
• To present the current state of preclinical and clinical development of epigenetic drugs for lymphoma.
• To focus on therapeutic strategies targeting histone methylation and acetylation.

Main Methods:

• Literature review of epigenetic alterations in B-cell non-Hodgkin lymphoma.
• Analysis of preclinical and clinical data for epigenetic drug development.
• Focus on histone methyltransferase and deacetylase inhibitors.

Main Results:

• Epigenetic alterations are key drivers in B-cell lymphoma pathogenesis.
• Numerous epigenetic drugs are in preclinical and clinical development.
• Targeting histone methylation and acetylation represents a promising therapeutic avenue.

Conclusions:

• Epigenetic dysregulation is central to B-cell lymphoma.
• Epigenetic therapies, particularly those targeting histone modifications, offer significant potential for improving patient outcomes.
• Further development and clinical translation of these therapies are crucial for lymphoma treatment.